 PolyPid Ltd NASDAQ: PYPD has received written responses from the FDA to a Type B meeting request that the company submitted regarding its development plan for its lead candidate, D-PLEX100. The FDA indicated that PolyPids proposal for a single Phase 3 pivotal study SHIELD I would be sufficient to establish clinical efficacy and safety to support approval of D-PLEX100 for the prevention of surgical site infections SSIs in colorectal surgery. 